ADVANCED MELANOMA
Clinical trials for ADVANCED MELANOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED MELANOMA trials appear
Sign up with your email to follow new studies for ADVANCED MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
PET scans may let melanoma patients stop therapy early
Disease control OngoingThis study tests whether doctors can safely stop standard anti-PD-1 immunotherapy earlier than usual for people with advanced melanoma that cannot be removed surgically. Using PET/CT scans and tumor biopsies as guides, researchers aim to see if shorter treatment still keeps the c…
Matched conditions: ADVANCED MELANOMA
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 26, 2026 05:57 UTC
-
Could a Two-Drug combo tame advanced melanoma?
Disease control OngoingThis study tested whether adding a drug called GM-CSF (sargramostim) to the immunotherapy ipilimumab helps people with advanced melanoma that cannot be surgically removed. About 245 participants were randomly assigned to receive ipilimumab alone or with GM-CSF. The main goal was …
Matched conditions: ADVANCED MELANOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 05:46 UTC
-
New Triple-Drug cocktail targets tough cancers
Disease control OngoingThis early-phase study tests a new drug (APX005M) combined with two existing immunotherapy drugs (nivolumab and ipilimumab) in people with advanced melanoma or kidney cancer who haven't had prior immunotherapy. The main goals are to check safety and find the best dose. About 26 a…
Matched conditions: ADVANCED MELANOMA
Phase: PHASE1 • Sponsor: Yale University • Aim: Disease control
Last updated May 26, 2026 05:42 UTC
-
New combo therapy shows promise for melanoma patients who failed previous treatment
Disease control OngoingThis study tests whether combining two immunotherapy drugs—talimogene laherparepvec (T-VEC) and pembrolizumab (Keytruda)—can shrink tumors in people with advanced melanoma that has stopped responding to standard anti-PD1/L1 therapy. About 43 adults with stage III or IV melanoma t…
Matched conditions: ADVANCED MELANOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Immune cells supercharged to fight advanced melanoma
Disease control OngoingThis early-stage trial tests a new treatment for advanced melanoma that has spread or cannot be removed. Doctors take immune cells from the patient's tumor, grow them in a lab, and give them back along with a drug called ANV419 to boost their activity. The main goal is to check s…
Matched conditions: ADVANCED MELANOMA
Phase: PHASE1 • Sponsor: University Hospital, Basel, Switzerland • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
New combo therapy offers hope for advanced melanoma patients
Disease control NO_LONGER_AVAILABLEThis program provides early access to an experimental treatment for adults with advanced melanoma that has worsened after standard anti-PD-1 therapy. Participants receive a combination of vusolimogene oderparepvec (VO) and nivolumab. The goal is to offer potential benefit to elig…
Matched conditions: ADVANCED MELANOMA
Sponsor: Replimune, Inc. • Aim: Disease control
Last updated May 19, 2026 12:00 UTC
-
New hope for melanoma patients when standard treatments fail
Disease control OngoingThis study tests a new drug called botensilimab, alone or with another drug, in 150 people with advanced melanoma that stopped responding to prior immunotherapy. The goal is to see if the drug can shrink tumors or slow the cancer's growth. Participants must have had prior anti-PD…
Matched conditions: ADVANCED MELANOMA
Phase: PHASE2 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated May 19, 2026 11:59 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: ADVANCED MELANOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC